Neal Bhatia on Muck Rack

Neal Bhatia

San Diego
As seen in: Dermatology Times, Practical Dermatology, The Practical Dermatology Podcast, Wiley Online Library, JAMA (The Journal of the American Medical Association), Healio Dermatology, HCP Live, MDEdge, MDedge Dermatology, Texas Medical Center, Journal of The American Academy of Dermatology (JAAD), International Journal of Cardiology, Heart Rhythm and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neal

Contact Neal, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Q&A: Discussing Imsidolimab for Generalized Pustular Psoriasis, With Neal Bhatia, MD

|
By Neal Bhatia
| consultantlive.com
After the acceptance by the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for imsidolimab in generalized pustular psoriasis (GPP) was announced, the HCPLive editorial team spoke in an interview with a dermatology leader regarding this move’s significance for patients with GPP.1,2 Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor could potentially add to the limited armamentarium of agents implemented within the GPP patient population.
Open in Who Shared View Duplicates (2) Issue with article?

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

|
By Neal Bhatia
| consultantlive.com
For individuals living with generalized pustular psoriasis (GPP), the potential for 2 flare-free years could represent a fundamental shift in what GPP treatment can offer.
Open in Who Shared View Duplicates (2) Issue with article?

What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

|
By Neal Bhatia
| consultantlive.com
The US Food and Drug Administration (FDA)'s acceptance of a Biologics License Application (BLA) for imsidolimab, Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor for generalized pustular psoriasis (GPP), could represent a meaningful step forward for a patient population with historically limited treatment options. The therapy is now under formal review as a potential addition to the emerging class of IL-36–targeted agents in dermatology.
Open in Who Shared View Duplicates (2) Issue with article?
See all 116 licensed articles (248 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified